152801-72-4

Basic information

• Product Name: 2-Bromo-1-(4-trifluoromethyl-phenyl)-ethanone O-methyl-oxime
• CAS NO: 152801-72-4
• Molecular Weight: 296.087
• Mol File: 152801-72-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-Bromo-1-(4-trifluoromethyl-phenyl)-ethanone O-methyl-oxime(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(4-trifluoromethyl-phenyl)-ethanone O-methyl-oxime(152801-72-4)
• EPA Substance Registry System: 2-Bromo-1-(4-trifluoromethyl-phenyl)-ethanone O-methyl-oxime(152801-72-4)

Safety Data

• Hazardous Substances Data: 152801-72-4(Hazardous Substances Data)

Upstream product

• 383-53-9 2-bromo-1-[4-(trifluoromethyl)phenyl]ethanone 
• 593-56-6 N-methoxylamine hydrochloride 

Downstream Products

• 152801-92-8 [2-Amino-2-(4-trifluoromethyl-phenyl)-ethyl]-phosphonic acid diethyl ester 
• 176759-67-4 [2-[(Z)-Methoxyimino]-2-(4-trifluoromethyl-phenyl)-ethyl]-phosphonic acid diethyl ester 

Relevant articles and documents

Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists

The free fatty acid receptor 1 (FFA1) plays a key role in amplifying glucose-stimulated insulin secretion in pancreatic β-cells. Most of the reported FFA1 agonists contain a biphenyl scaffold, which is associated with toxicity as verified by Daiichi Sankyo. Herein, we describe the systematic exploration of a non-biphenyl scaffold to improve the druggability of GW9508 (β-oxidation, Fsp3 = 0.13, tPSA = 58.5 ?2) directed by Fsp3 and tPSA values. All these optimizations ultimately led to the identification of compound 21, an unconventional agonist (EC50 = 72.5 nM) bearing a methyl oxime ether scaffold. Moreover, compound 21 revealed improved drug-like properties (Fsp3 = 0.23, tPSA = 86.6 ?2) when compared to GW9508 (Fsp3 = 0.13, tPSA = 58.5 ?2) and an even higher binding efficiency index (BEI = 15.3) than TAK-875 (BEI = 14.3). Further pharmacological studies suggested that compound 21 has a considerable hypoglycemic effect in both normal and type 2 diabetic mice with a low risk of hypoglycemia. In addition, the docking study promoted our understanding of the ligand-binding pocket. This information might help towards the design of more promising new molecular entities.